SCHEMBL1968423

SCHEMBL1968423

CCOC(=O)C(NC(C)=O)C(=O)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.55
CA1 P00915 2/20 0.55
CA2 P00918 2/20 0.55
CA9 Q16790 2/20 0.55
NPC1 O15118 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
LMNA P02545 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.44
MMP8 P22894 2/20 0.44
PIN1 Q13526 1/20 0.44
ALDH1A1 P00352 2/20 0.43
MAPT P10636 1/20 0.43
GAA P10253 1/20 0.42
RAB9A P51151 1/20 0.42
MTNR1A P48039 3/20 0.42
MTNR1B P49286 3/20 0.42
PGR P06401 1/20 0.41
ADRA2A P08913 1/20 0.41
ADRA2B P18089 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL5351689 0.98 CA12 (0.54) CA12CA1CA2CA9NPC1
Bromide SCHEMBL7614615 0.98 CA12 (0.54) CA12CA1CA2CA9NPC1
SCHEMBL28739371 0.89 NPC1 (0.50) CA12CA1CA2CA9NPC1
SCHEMBL28569685 0.88 CA12 (0.55) CA12CA1CA2CA9NPC1
SCHEMBL11636179 0.88 CA12 (0.55) CA12CA1CA2CA9NPC1
SCHEMBL2056927 0.85 KMT2A (0.47) CA12CA1CA2CA9KMT2A
SCHEMBL25015371 0.85 LMNA (0.51) CA12CA1CA2CA9MEN1
SCHEMBL15947013 0.85 LMNA (0.48) CA12CA1CA2CA9MEN1
Toluene SCHEMBL28212958 0.84 LMNA (0.52) CA12CA1CA2CA9NPC1
SCHEMBL1339677 0.83 LMNA (0.48) CA12CA1CA2CA9NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-01 US disclosed
US-7994336-B2 Azetidine compounds as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2011-08-09 US disclosed
EP-2334643-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES Actelion Pharmaceuticals Ltd. (CH) 2011-06-22 EP disclosed
US-20100222600-A1 AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-02 US disclosed
WO-2010044054-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD (CH) 2010-04-22 WO disclosed
EP-0587533-B1 Process for the preparation of alpha-aminoketone salts CIBA GEIGY AG (CH) 1997-03-12 EP disclosed
US-5322964-A Process for the preparation of alpha-aminoketone salts CIBA-GEIGY CORPORATION (US) 1994-06-21 US disclosed
EP-0587533-A2 Process for the preparation of alpha-aminoketone salts CIBA-GEIGY AG (CH) 1994-03-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222600-A1 AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY1R CA12 3138/4885CA1 1625/4885CA2 1591/4885
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES HCRTR2, HCRTR1, HRH3 CA12 3489/4885CA1 2155/4885CA2 985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.